CervoMed Inc. Files 8-K with Regulatory Updates

TL;DR

CervoMed (CRVO) filed an 8-K on Dec 5th covering events from Dec 1st. Expect updates on Reg FD, other events, and financials.

AI Summary

CervoMed Inc. filed an 8-K on December 5, 2025, reporting on events that occurred on December 1, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Diffusion Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This 8-K filing provides important updates and disclosures from CervoMed Inc. to investors and the public regarding recent events and financial information.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting current events and financial information, not indicating any immediate significant risks.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• Diffusion Pharmaceuticals Inc. (company) — Former company name
• 20 Park Plaza, Suite 424, Boston, Massachusetts 02116 (location) — Principal executive offices address
• December 1, 2025 (date) — Date of earliest event reported
• December 5, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20251205_8k.htm (8-K) — 38KB
• ex_896196.htm (EX-99.1) — 25KB
• ex_896197.htm (EX-99.2) — 26KB
• logosmlr.jpg (GRAPHIC) — 4KB
• 0001437749-25-037025.txt ( ) — 244KB
• crvo-20251201.xsd (EX-101.SCH) — 3KB
• crvo-20251201_def.xml (EX-101.DEF) — 12KB
• crvo-20251201_lab.xml (EX-101.LAB) — 15KB
• crvo-20251201_pre.xml (EX-101.PRE) — 12KB
• crvo20251205_8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure Press Releases On December 2, 2025, CervoMed Inc. (the "Company," "we" or "us") issued a press release (the "December 2 Press Release") announcing new plasma biomarker data from our Phase 2b RewinD-LB trial (the "RewinD-LB Trial") demonstrating neflamapimod treatment led to improvements in neuroinflammation and neurodegeneration in patients with dementia with Lewy bodies ("DLB") presented at the 18 th Clinical Trials on Alzheimer's Disease ("CTAD") Conference in San Diego, California on December 1, 2025. A copy of the December 2 Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference. On December 4, 2025, we issued a press release (the "December 4 Press Release") announcing that clinical investigators shared the full results of the RewinD-LB Trial in a late-breaking oral session at the CTAD Conference on December 4, 2025. A copy of the December 4 Press Release is attached hereto as Exhibit 99.2 and incorporated herein by reference. Presentations Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including the data and other information from the RewinD-LB Trial presented at the CTAD Conference, has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission ("SEC") and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or re

01

Item 8.01 Other Events The information set forth, (i) with respect to the December 2 Press Release, in the first two paragraphs and under the heading, "Treatment Benefit Associated with Biomarker Measurements," and (ii) with respect to the December 4 Press Release, in the first paragraph and under the heading, "Results from the Phase 2b RewinD-LB Trial," is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 7.01 is furnished and not filed: Exhibit No. Description 99.1 Press Release, issued December 2, 2025 99.2 Press Release, issued December 4, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 5, 2025 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR